GlaxoSmithKline - Big Pharma's Q2 2010 Earnings Report

FiercePharma says: GlaxoSmithKline announced a $2.36 billion charge to second-quarter earnings, to cover the cost of resolving several legal problems including the Avandia settlement, but also a $750 million deal to dispose of a U.S. manufacturing investigation.


  • Q2 sales £7.0 billion (level); progress in diversification strategy offsets US decline.
  • H1 total sales £14.4 billion (+7%); sales excluding pandemic products +1%
  • Sustained pipeline delivery and development of portfolio.
  • Ongoing efforts to resolve long-standing legal cases; pre-announced Q2 legal charge of £1.57 billion
  • Continued focus on cost control and strong cash generation.

See GSK's current stock quote from CNN Money

GSK's website:
Full release: GSK's earnings release

GlaxoSmithKline - Big Pharma's Q2 2010 Earnings Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.